Clinical trial · Interventional
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
NCT00922896CI-TRIAL-00008516completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine, Cisplatin, Erlotinib (Tarceva) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GPE
- description
- Gemcitabine-Cisplatin-Erlotinib
- interventionNames
- Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
Primary outcomes (1)
- measure
- To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer
- timeFrame
- Clinically assessed every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age older than 18 * Younger than 75 * ECOG performance status 0 or 1 * Histologically confirmed adenocarcinoma of the pancreas * Metastatic pancreatic cancer * No prior chemotherapy for metastatic pancreatic cancer * A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT) Exclusion Criteria: * A patient with no measurable disease * A patient who received previous palliative chemotherapy for pancreatic cancer * A patient with locally advanced pancreatic cancer * A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year * A patient with previous active or passive immunotherapy * A pregnant or lactating patient
References
Publications (1)
- DERIVEDHwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2012 Dec;30(6):2371-6. doi: 10.1007/s10637-012-9792-z. PMID 22302349